Designing A Medicare Prescription Drug Benefit: Issues, Obstacles, And Opportunities

McClellan, Mark; Spatz, Ian D.; Carney, Stacie

doi:10.1377/hlthaff.19.2.26

Cited by 19 publications

(12 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the likelihood of patients exceeding a cap depends on insurance features, such as copayments and deductibles, that affect the distribution of cost between patients and the plan. 20 Paradoxically, a benefit design with lower co-payments can lead to patients exceeding the cap quicker because a larger share of drug costs is paid by the plan and applied to the cap.…”

Section: Commentmentioning

confidence: 99%

Impact of an Annual Dollar Limit or "Cap" on Prescription Drug Benefits for Medicare Patients

Tseng

Brook²,

Keeler³

et al. 2003

JAMA

View full text Add to dashboard Cite

Section: Commentmentioning

confidence: 99%

Impact of an Annual Dollar Limit or "Cap" on Prescription Drug Benefits for Medicare Patients

Tseng

Brook²,

Keeler³

et al. 2003

JAMA

View full text Add to dashboard Cite

“…Cost-sharing strongly influences use of health care resources. 3 Yet, cost-sharing in many proposals, which reflects cost-sharing in current sources of drug coverage, 4,5 is high. For example, one leading proposal would require a $53 monthly premium, a $250 annual deductible, and a 50% co-payment until the recipient paid $3500 out-of-pocket each year.…”

Section: A Fter Years Of Intense De-mentioning

confidence: 99%

Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease

Federman¹,

Adams²,

Ross‐Degnan³

et al. 2002

ACC Current Journal Review

View full text Add to dashboard Cite

“…for a more equal distribution of other goods). See also the proceedings of the Conference on National Approaches to Pharmacare (Health Canada 1998) and Lexchin (2001) for general discussion of efficiency and redistributive issues in a policy context and McClellan, Spatz, and Carney (2000) and Bhattacharya and Lakdawalla (2002) for some recent perspectives for the United States.…”

mentioning

confidence: 99%

Distributional effects of ‘general population’ prescription drug programs in Canada

Alan

Crossley

Grootendorst

et al. 2005

Canadian J of Economics

View full text Add to dashboard Cite

Canadian household prescription drug expenditures are studied using the Statistics Canada Family Expenditure Survey masterfiles for periods that include the introduction of provincial 'general population' prescription drug programs. Budget shares for non-senior households are examined over time using non-parametric regression, parametric 'difference-in-difference' techniques, and quantile regression methods. The evidence suggests that while program effects are muted when there are high deductibles, a non-senior prescription drug subsidy is more redistributive than an equal-cost proportional income transfer, in part because of differential private health insurance coverage by income. This is in contrast to previous evidence on Canadian senior prescription drug subsidies. JEL classification: I18, J42Les effects de redistribution des programmes d'assurance-me´dicaments pour la population en ge´ne´ral au Canada. Les auteurs e´tudient les de´penses des me´nages canadiens pour les me´dicaments sur ordonnance a`l'aide des donne´es de l'Enqueˆte sur les de´penses des For assistance with the data we thank Martin Browning familles pour des pe´riodes qui couvrent les moments ou`on a mis en place des programmes provinciaux d'assurance-me´dicaments pour la population en ge´ne´ral. Les portions des budgets des me´nages qui ne sont pas des me´nages d'aine´s sont analyse´es a`l'aide de me´thodes de re´gression non-parame´trique, de techniques parame´triques de ''diffe´rence dans les diffe´rences'', et de re´gression quantile. Les re´sultats sugge´rent que bien que les effects de ces programmes soient assourdis quand les montants de´ductibles a`la base sont e´leve´s, une subvention pour les me´dicaments sous ordonnance pour les non-aıˆne´s a un effet de redistribution plus important qu'un transfert de revenu proportionnel d'un couˆt e´gal, en partie a`cause des diffe´rences dans la couverture des re´gimes prive´s d'assurance-sante´selon les niveaux de revenus. Cela contraste avec les re´sultats d'e´tudes ante´rieures sur l'impact des assurance-me´dicaments pour les aıˆne´s au Canada.

show abstract

Designing A Medicare Prescription Drug Benefit: Issues, Obstacles, And Opportunities

Cited by 19 publications

References 3 publications

Impact of an Annual Dollar Limit or "Cap" on Prescription Drug Benefits for Medicare Patients

Impact of an Annual Dollar Limit or "Cap" on Prescription Drug Benefits for Medicare Patients

Supplemental insurance and use of effective cardiovascular drugs among elderly medicare beneficiaries with coronary heart disease

Distributional effects of ‘general population’ prescription drug programs in Canada

Contact Info

Product

Resources

About